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ABSTRACT 
A short and efficient synthesis of novel tetracyclic Kynurenic acid analogues, isolated from chestnut 
honey, is described. The crucial step of the strategy was a MW-assisted cyclization of enamines of 
ethyl dioxohexahydropyrrolizine and 2,3-dioxooctahydroindolizine carboxylates to obtain 2,3,6,11b-
tetrahydro-1H-pyrrolizino[2,1-b]quinoline-5,11-dione and 5,8,9,10,11,11a-hexahydroindolizino[2,1-
b]quinoline-6,12-dione, respectively. Because of its modular nature, the synthetic strategy can have 
value as a general method for the preparation of compounds containing these new heterocyclic 
scaffolds. 
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Kynurenic acid (KYNA), an endogenous, non-selective antagonist of ionotropic glutamate receptors, 
is commonly considered as a final metabolite of tryptophan via the kynurenine pathway (KP).  
Recent studies provided evidence for an important role of kynurenine pathway metabolites in several 
neurological, psychiatric and neurodegenerative diseases, with particular emphasis on the putative 
neuroprotective activity exerted by KYNA.1 The biological activity of KYNA is due to its 
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antagonizing capacity toward the glycine site of the NMDA (N-methyl-D-aspartate) receptors and/or 
the cholinergic α7 nicotine receptors. However, concomitant or alternative involvement of other 
pharmacological targets responsible for its electrophysiological and behavioral actions cannot be 
excluded.2 
KYNA is present in several food products, with the highest known concentrations found in chestnut 
honey.3 6-hydroxy-KYNA and KYNA are also present in the plant kingdom with a taxa-specific 
distribution of the former.4 The observation of significant levels of KYNA in different medicinal 
plants suggested that it may contribute to their therapeutic potential, especially in the digestive 
system.5  
Interestingly, recent studies consistently demonstrated that chestnut honey also contains tetracyclic 
KYNA derivatives, with a tetrahydropyrrolizinoquinolinedione (compound 1, figure 1) or a 
hexahydroindolizinoquinolinedione (compound 2, figure 1) core.6 These substances originate mainly 
from the nectar of male flowers of chestnut.7 Their biosynthesis is also intriguing, as they probably 
derive from KYNA,7 differently from the isomeric fungal metabolite tetrahydroquinolactacide,8 
whose biosynthesis most likely starts from anthranilic acid.9  
Currently, the biological function(s) and therapeutic potentiality of derivatives 1 and 2 are unknown. 
Hence, the aim of the present study was to set up a synthetic procedure for these new quinolinone 
alkaloids which may - in principle - have value in the preparation of the natural compounds 
themselves as well as in synthesizing analogues for structure-activity relationship studies. 
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Figure 1. Structures of compounds 1 and 2 isolated from chestnut honey 
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Initially, we focused on the synthesis of compound 1. We envisioned that the most straightforward 
approach could be based on the construction of the tetracyclic system starting from kynurenic acid. 
Thus, disconnection at the amide bond level of the compound 1 gave as precursor the key intermediate 
A, which should be accessible by metal-catalyzed cross-coupling reaction between a functionalized 
kynurenic acid B and a boronic acid C (Scheme 1, path I) 
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Scheme 1. Retrosynthetic analyses of compound 1 
 
The N-benzyl protected coupling partner B (compound 5) was easily obtained by treatment of N-
benzylaniline 3 with DMAD (dimethyl acetylenedicarboxylate) in methanol at reflux, followed by 
cyclization with Eaton’s reagent10 to give N-benzyl kynurenic acid methyl ester (4).  Iodination11 
provided intermediate 5 in good yield.  
The N-Boc protected partner C (compound 6) was obtained from commercially available N-Boc 
pyrrole-2- boronic acid by hydrogenation with PtO2 in ethyl acetate at room temperature (Scheme 2). 
Once prepared the two fragments, we had to couple them to obtain compound 7. 
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Scheme 2. Synthesis of compound 9. Reagents and conditions: a) DMAD, MeOH, reflux, 85%; b) P2O5/MeSO3H, N2, 50 
°C, 82%; c) I2, CAN, N2, 50-80 °C, 98%; d) Pd(PPh3)4, NaHCO3, DME, 2-pyrrol boronic acid, N2, reflux, 64%; e) H2 40 
atm, Pd/C 10%, MeOH, rt. 
 
Initial efforts to effect the carbon-carbon coupling reaction, carried out using Pd(PPh3)4 and  aqueous 
Na2CO3 in toluene at 80 °C, were unsuccessful. Various attempts of coupling made with different 
bases (K2CO3, K3PO4, CsCO3) different phosphine ligands (Pd(dppf), Pd(dba)2) and a variety of 
solvents (dioxane, THF and DME) always gave complex reaction mixtures.  
Stille cross coupling reaction was also unsuccessful. Stannane 8 was prepared from N-Boc pyrrolidine 
and n-Bu3SnCl with secBuLi in THF. Reaction of this latter with 5 in the presence of Pd(PPh3)4 in 
dioxane12 did not provide the expected product (Scheme 2). 
A possible explanation of these failures in coupling reactions is the poor reactivity of alkyl boronic 
acids. Aryl-alkyl Suzuki-Miyaura cross-couplings are often complicated by reduction and 
isomerization side reactions as a result of the presence of β-hydrogen atoms in the alkyl group.13 
The use of N-Boc-2-pyrroleboronic acid instead of the corresponding alkyl boronic acid 6 easily 
afforded the coupling product 9,14 but the successive reduction of the ring together with the removal 
of the protecting benzyl group failed, even by hydrogenation at high pressure15 (Scheme 2). 
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Thus, an alternative route was pursued. We envisioned that the functional quinolone skeleton of 
compounds 1 and 2 might be assembled by the application of the Winterfeldt oxidation of indoles.16 
This reaction has provided an efficient method for indole-quinolone transformations in the total 
synthesis of the potent antitumor agent camptothecin 17 and of the antibiotics quinolactacine A18 and 
B.19 
As reported by Husson and coworkers,20 pyrrolo[3,4-b]-quinoline-3,9-diones can be obtained by 
Winterfeldt oxidation (O2, t-BuO-K+, DMF) of N(b) substituted tetrahydropyrido[3,4-b]indol-1-ones. 
Thus, we identified compound D as a new key intermediate (Scheme 1, path II).  
As the removal of benzyl group had been troublesome (see scheme 2), we chose the 
(phenylsulfonyl)ethyl group for N-protection. Indeed, the group can be easily removed by treatment 
with strong bases such as t-BuOK,21 which is also used to perform Winterfeldt oxidation. 
Thus, commercially available indole-2-carboxylic acid methyl ester 10 was treated with 2-
phenylsulfonylethyl chloride in presence of NaH and DMF to obtain compound 11. Hydrolysis of the 
ester to the corresponding acid 12 was achieved under basic conditions using LiOH in THF/H2O 1:1 
(Scheme 3). 
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Scheme 3. Synthesis of compound 14. Reagents and conditions: a) ClCH2CH2SO2Ph, NaH, DMF, N2, rt, 61%; b) 
LiOH.H2O, THF/H2O 1:1, 98%; c) EDCI (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), HOBt 
(hydroxybenzotriazole), prolinol, THF, N2, rt, 86%; d) TFA, 1,2-dichloromethane, 50 °C, N2, 12%.  
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The condensation of 12 with prolinol gave compound 13, which was cyclized by TFA in 1,2-
dichloroethane22 (Scheme 3) to obtain compound 14. However, the very poor yield of this reaction 
prevented us to pursue this strategy.  
In our last approach (Scheme 1, path III), retrosynthetic cleavage at the C4/C5a and NH/C2 bonds 
dissected the target molecule 1 into an aniline and the intermediate E.23   
Ethyl-2-pyrrolidinylacetate 17 was prepared in two steps in 32% overall yield by radical alkylation 
of pyrrole with ethyl iodoacetate followed by reduction with rhodium on alumina in glacial acetic 
acid. Alternatively, the compound was obtained in three steps from commercially available 2-
pyrrolidinone in an improved 53% yield.24 The synthesis of 1-carbethoxy-2,3-dioxopyrrolizidine 19 
was carried out using Adams’ method.25  Reaction with diethyl oxalate in presence of sodium ethoxide 
gave compound 19 in 80% yield. Condensation with aniline in toluene produced compound 21 in 
good yield. Intramolecular cyclization of the enamine performed under various conditions 
(P2O5/Me3SO3H, H2SO4 and PPA) did not allow us to obtain the desired compound, giving only 
decomposition products, most probably due to the instability of enamines in an acidic environment. 
When the reaction was performed thermally in a neutral medium (boiling diphenyl ether) the desired 
compound 1 was obtained in low yield (24%) after a long reaction time (Scheme 4). To overcome 
this limitation we shifted to microwave heating. After several attempts (solvent free26 and in 
acetonitrile at various temperatures between 130 °C and 180 °C), we found that the desired compound 
could be obtained in a satisfactory 45% yield heating at 240 °C in DMF for 2h. 
The compound was fully characterized by MS and NMR spectroscopy. Disappointingly, when we 
compared the 1H NMR spectrum of compound 1 dissolved in CDCl3 (20 mg/mL) with the spectrum 
of the natural compound reported in the literature in the same solvent,6 we found some discrepancies. 
Specifically, the reported chemical shift of the aromatic proton on carbon 7 was 7.57 ppm, whereas 
in our compound the chemical shift of the same proton was 7.79 ppm. Analogously, the signal of the 
NH proton was 9.74 ppm in the literature paper and 11.15 ppm in our spectrum. In 13C NMR spectrum 
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of the isolated compound the signals of C6a and C10a were overlapped at 139.8 ppm, whereas the 
same signals in our spectrum were at 141.1 and 140.2 ppm. 
However, we noticed that increasing the dilution of the sample (5mg/mL), the above reported signals 
shifted upfield and at a concentration of 1mg/mL, the spectra of compound 1 completely matched 
those reported in the literature (Figure 2). Moreover, the signal of the NH proton, sharp at high 
concentration (20 mg/mL), became progressively broader during the dilution process, a behaviour 
indicative of the reduced ability of the NH proton to form hydrogen bonds. 
This evidence suggested that compound 1 in concentrated CDCl3 solution gives strong intermolecular 
hydrogen bond interactions, which progressively weaken with the dilution of the sample. The 
formation of hydrogen bonds was confirmed by the shift of NH and aromatic hydrogen signals in the 
NMR spectra of compound 1 (10 mg/mL) run at different temperatures (10 °C, 15 °C, 25 °C). (see 
SI, figures 1S and 2S).  
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Figure 2. Effect of the concentration of compound 1 on the chemical shift of aromatic and N-H protons (1H NMR, 600 
MHz, CDCl3, expanded region 7-12 ppm) 
 
The developed synthetic protocol was exploited for the synthesis of the six-membered ring compound 
2. Ethyl 2-piperidinylacetate 18 was prepared by hydrogenation of the commercially available 2-
pyridylacetate 16 with PtO2 in ethanol and 6M HCl. Reaction with diethyl oxalate gave the cyclized 
compound 20, which was then converted into the corresponding enamine 22 in 54% yield. (Scheme 
4). Microwave cyclization afforded compound 2, whose spectroscopic properties matched with those 
of the natural compound isolated from chestnut honey.  
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Scheme 4. Synthesis of compounds 1 and 2. Reagents and conditions: a) Rh/Al2O3 5%, CH3COOH, H2, 1 atm, 79% b) 
PtO2, EtOH, HCl 6M, H2 1 atm; 74% c) diethyl oxalate, EtONa, EtOH, reflux, N2, 80% for 19 and 70% for 20; d) aniline, 
toluene, reflux, 70% for 21 and 53% for 22; e) DMF, 245 °C, MW, 45% for 1 and 60% for 2. 
 
To summarise, the first total synthesis of two novel tetracyclic KYNA derivatives isolated from 
chestnut honey was designed and carried out. The crucial step of our strategy was a MW-assisted 
cyclization of enamines of ethyl 2,3-dioxooctahydroindolizine and dioxohexahydropyrrolizine 
carboxylates. Further synthetic studies and evaluation of biological activity of the obtained tetracyclic 
compounds are in progress. 
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A. Supplementary data Supplementary data associated with this article, including experimental 
procedures and copies of NMR spectra of the new compounds, can be found, in the online version, at 
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